|
Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
Research Funding - EMD Serono (Inst); Merck (Inst) |
|
|
Consulting or Advisory Role - Puma Biotechnology |
Speakers' Bureau - Nanobiotix; Roche |
Travel, Accommodations, Expenses - Sanofi/Regeneron |
|
|
No Relationships to Disclose |
|
|
Expert Testimony - Merck; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Amgen; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Incyte; Loxo |
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Pfizer (I); Roche/Genentech |
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech |
Speakers' Bureau - Novartis |
Research Funding - AstraZeneca/MedImmune (Inst) |
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology |
|
|
Stock and Other Ownership Interests - Theravance |
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Roche |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Roche |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Incyte; MedImmune; Merck Serono; Merck Sharp & Dohme; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma; Syndax; Ultimovacs |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
Vladimir Ivanovich Vladimirov |
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Employment - HM Hospitales; START |
|
Stock and Other Ownership Interests - International Cancer Consultants; Oncoart Associated; START |
Honoraria - HM Hospitales |
Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER |
Speakers' Bureau - Novartis |
Research Funding - AstraZeneca; BeiGene; Novartis; START |
Travel, Accommodations, Expenses - Roche/Genentech |
Other Relationship - Investigational Therapeutics in Oncological Sciences |